# Prognostic and Predictive Impact of uPA/PAI-1

> **NCT01317108** · PHASE3 · COMPLETED · sponsor: **Universitätsklinikum Hamburg-Eppendorf** · enrollment: 689 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** CMF Chemotherapy

## Key facts

- **NCT ID:** NCT01317108
- **Lead sponsor:** Universitätsklinikum Hamburg-Eppendorf
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1993-06
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 689 (ACTUAL)
- **Last updated:** 2017-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01317108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01317108, "Prognostic and Predictive Impact of uPA/PAI-1". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01317108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*